Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct
defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function
and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it
is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow
through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation
observed in heart failure.